S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
OncLive® On Air
00:00
SG plus pembrolizumab vs chemo+pembro (efficacy)
Heather McArthur presents PFS improvement for SG+pembrolizumab versus chemo+pembrolizumab across subgroups, OS immature.
Play episode from 11:15
Transcript
